Hemispherx in hep C/HIV pact with Empire Health
Hemispherx Biopharma, which focuses on the development of nucleic acidsto enhance antiviral defense systems, has entered into a strategic partnership with Empire Health Resources, the USA's leading privately-held health care management firm.
Under the agreement, Empire Health will provide the accrual and retention of all patients for Hemispherx' clinical trials of Ampligen (poly I: poly C12U), for the treatment of HIV, as well as protocols for the treatment of hepatitis C and the co-infection of hepatitis C virus and HIV. The therapy is currently in Phase IIb clinical trials.
William Carter, Hemispherx' chief executive, said that the growing prevalence of co-infection of HIV and hepatitis C among people with AIDS "has led to the development of a greater emphasis on the evolution of immune-based therapies."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze